<DOC>
	<DOC>NCT00688558</DOC>
	<brief_summary>The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with simvastatin 40 mg in patients with low HDL</brief_summary>
	<brief_title>Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Patients having lipid values as indicated below: HDLC ≤ 1.0 mmol/L (40 mg/dL) TG ≤4.5 mmol/L (400 mg/dL) Patients with CHD or CHD risk equivalent Male and females between 18 and 70 years of age (female patients must be postmenopausal, surgically sterile or using an acceptable form of contraception) Body Mass Index of ≥ 35 kg/m2 Females that are pregnant or breastfeeding, and females of child bearing potential who are not using an effective method of contraception Concomitant use of medications identified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>